Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 13

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 13
---
 issued separately in this offering. Pursuant to this prospectus, we are also offering 2,260,000 common shares issuable from time to time upon the exercise of the warrants offered hereby. |
| Public offering price           | $3.10 per Unit.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Common shares to be outstanding | 15,832,737 common shares (if none of the warrants issued in this offering are exercised).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Use of Proceeds                 | We intend to use the net proceeds from this offering to fund our Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using our doxorubicin tip loaded dissolvable microarray needle skinpatch. We may also use the net proceeds of this offering to expand our exploratory phase 2 clinical trial to a pivotal trial and/or to expand our trials to cover other non-melanoma skin diseases. We will use any remaining net proceeds for general corporate purposes and working capital. See "Use of Proceeds."                                                                                                                                                                                             |
| Voting rights                   | Each outstanding common share will be entitled to one vote on all matters submitted to a vote of shareholders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Listings                        | Our common shares and Public Warrants are listed on Nasdaq under the symbols "MDCX" and "MDCXW," respectively. The warrants offered hereby will not be listed on any U.S. securities exchange.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dividend policy                 | We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors.                                                                                                                                 |
| Risk factors                    | See "Risk Factors" and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares and warrants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div align='center'>6</div>

Except as otherwise noted, all information contained in this prospectus assumes:

The number of common shares that will be outstanding after this offering is based on 13,572,737 common shares outstanding as of May 21, 2025.

<div align='center'>